While most tumor immunotherapies involve CD8+ T cells, the data we present here are also consistent with a reliance upon CD4+ T cells, either for their own cytokine production or for their ability to help mount a protective B cell response; these possibilities cannot be ruled out [53]. Here, CD8A is linked to neoplasm.